---
id: 118
title: Varicella-Zoster Virus (VZV) Management
category: organisms
subcategory: viruses
tags: [VZV, varicella, zoster, shingles, chickenpox, acyclovir, valacyclovir]
difficulty: medium
---

## Question

How is VZV managed? Use the **"Acyclovir for Severe Varicella/Zoster, Valacyclovir for Shingles, Consider Complications"** framework.

## Answer

### **VZV Clinical Syndromes:**

**Primary Infection:**
- **Varicella (Chickenpox):** **Vesicular rash** (centripetal distribution: trunk → extremities), **all stages present** (macules, vesicles, crusts)

**Reactivation:**
- **Herpes Zoster (Shingles):** **Dermatomal vesicular rash**, usually **unilateral**, pain precedes rash

### **Treatment:**

| Syndrome | Treatment | Duration | Indications |
|----------|-----------|----------|-------------|
| **Varicella (chickenpox)** - **uncomplicated** | **Supportive care** OR **acyclovir 800mg PO 5×/day** | **5-7 days** | Treat if: **Age >12 years**, **high-risk** (pregnancy, immunocompromised), **complications** |
| **Varicella - severe/complicated** | **Acyclovir 10 mg/kg IV q8h** | **7-10 days** | Pneumonia, encephalitis, hepatitis, hemorrhagic |
| **Herpes zoster (shingles)** | **Valacyclovir 1g PO TID** OR **acyclovir 800mg PO 5×/day** | **7 days** | **Start within 72h** of rash onset (all patients >50 years OR immunocompromised) |
| **Disseminated zoster** | **Acyclovir 10 mg/kg IV q8h** | **7-10 days** | **≥2 dermatomes**, immunocompromised, visceral involvement |
| **Zoster ophthalmicus** | **Valacyclovir 1g PO TID** + **ophthalmology consult** | **7-10 days** | **Hutchinson sign** (vesicles on nose tip) = high risk for ocular involvement |

### **Complications:**

**Varicella Complications:**
- **Pneumonia** (adults, immunocompromised) - most common cause of death
- **Encephalitis** (cerebellar ataxia in children, meningoencephalitis in adults)
- **Secondary bacterial superinfection** (*S. aureus*, GAS) - cellulitis, necrotizing fasciitis
- **Hemorrhagic varicella** (immunocompromised)
- **Congenital varicella syndrome** (maternal infection <20 weeks gestation)

**Zoster Complications:**
- **Post-herpetic neuralgia (PHN):** **Pain >90 days** after rash onset, **most common complication** (10-30%, higher in elderly)
- **Zoster ophthalmicus:** Ocular involvement (keratitis, uveitis, retinitis), **can cause blindness**
- **Ramsay Hunt syndrome:** Facial nerve palsy + ear vesicles + hearing loss (geniculate ganglion)
- **Disseminated zoster:** **≥2 dermatomes** OR visceral involvement

## Key Points

### **When to Treat Zoster:**
- **All patients >50 years old**
- **Immunocompromised** (any age)
- **Ophthalmic zoster** (V1 distribution)
- **Severe pain** or **extensive rash**
- **Ideally within 72h** of rash onset (but still treat if >72h if high-risk or new lesions forming)

### **Post-Herpetic Neuralgia (PHN) Prevention:**
- **Antiviral therapy** (reduces PHN risk if started within 72h)
- **Analgesics** during acute phase
- **PHN treatment:** Gabapentin, pregabalin, tricyclic antidepressants (amitriptyline), topical lidocaine

### **Zoster Vaccines:**
- **Shingrix (recombinant):** **Preferred**, 2 doses (0, 2-6 months), **>90% efficacy**, **age ≥50 years**
- **Zostavax (live attenuated):** No longer preferred (lower efficacy ~50%), contraindicated if immunocompromised

### **Post-Exposure Prophylaxis (Varicella):**

**Indications (high-risk exposed individuals):**
- Immunocompromised, pregnancy, newborns

**Options:**
- **VariZIG (varicella-zoster immune globulin):** 125 units/10kg IM **within 10 days** of exposure
- **Acyclovir prophylaxis** (alternative): 800mg PO 4×/day × 5-7 days (start 7-10 days post-exposure)
- **Post-exposure vaccination:** If no contraindications, give within 3-5 days

### **Clinical Pearls:**
- **Chickenpox:** Treat if age >12, high-risk, or complicated (acyclovir 800mg 5×/day)
- **Shingles:** Valacyclovir 1g TID × 7 days (start within 72h, treat all >50 years or immunocompromised)
- **Zoster ophthalmicus:** Ophthalmology consult + valacyclovir
- **PHN:** Most common zoster complication (pain >90 days)
- **Shingrix vaccine:** Recommended age ≥50 (>90% efficacy)
- **Disseminated/severe:** IV acyclovir 10 mg/kg q8h

## Sources

- [CDC: VZV Guidelines 2024]
- [AAD: Herpes Zoster Guidelines 2023]

## Media

N/A
